More research (I hope these articles are helpful to some. Of course, you can wait for the analysts to say its OK to buy. What will Biomira shares be worth then?) This article is included because of its reference to liposome encapsulation in chemotherapy.
"
Full Text of this Article
Reprint (PDF) Version of this Article
Similar articles found in:
JCO Online
PubMed
PubMed Citation
Search Medline for articles by:
Valero, V. || Hortobagyi, G. N.
Alert me when:
new articles cite this article
Download to Citation Manager
Journal of Clinical Oncology, Vol 17, Issue 5 (May), 1999: 1425
¸ 1999 American Society for Clinical Oncology
Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer
Vicente Valero, Aman U. Buzdar, Richard L. Theriault, Nozar Azarnia, Gustavo A. Fonseca, Jie Willey, Michael Ewer, Ronald S. Walters, Bruce Mackay, Donald Podoloff, Daniel Booser, Lily W. Lee, Gabriel N. Hortobagyi
From the University of Texas M.D. Anderson Cancer Center, Houston, TX; and The Liposome Company, Inc, Princeton, NJ.
Address reprint requests to Vicente Valero, MD, University of Texas M.D. Anderson Cancer Center, Department of Breast Medical Oncology, 1515 Holcombe Blvd, Box 56, Houston, TX 77030; email vvalero@mdacc.org
PURPOSE: To determine the efficacy and safety profile, including the risk for cardiac toxicity, of liposome-encapsulated doxorubicin (TLC D-99), fluorouracil (5-FU), and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer (MBC).
PATIENTS AND METHODS: Forty-one women were registered in this phase II study. All patients had measurable disease and no previous chemotherapy for MBC. Treatment consisted of TLC D-99 60 mg/m2 and cyclophosphamide 500 mg/m2 on day 1 and 5-FU 500 mg/m2 on days 1 and 8 every 3 weeks. Serial cardiac monitoring, including endomyocardial biopsies, was performed.
RESULTS: The overall response rate was 73% (95% confidence interval, 57% to 86%). The median duration of response was 11.2 months, the median time to treatment failure was 8.1 months, and the median overall survival duration was 19.4 months. The median number of cycles per patient was 10. The median cumulative dose of TLC D-99 was 528 mg/m2. Ten patients required hospitalization for febrile neutropenia. Nausea/vomiting, stomatitis, and fatigue higher than grade 2 occurred in 12%, 15%, and 41% of patients, respectively. Twenty-one patients reached a cumulative doxorubicin dose greater than 500 mg/m2. Three patients (7%) were withdrawn from the study due to protocol-defined cardiac toxicity, two because of a decrease in left ventricular ejection fraction to 40%, and one because her endomyocardial biopsy result was grade 1.5. One patient had congestive heart failure that was probably nonanthracycline related.
CONCLUSION: This chemotherapy regimen, including TLC D-99, was highly active against MBC and associated with low cardiac toxicity despite high cumulative doses of doxorubicin.
Presented in part at the Chemotherapy Foundation Symposium XII, November 9-11, 1994, New York, NY, and at the 14th Annual Meeting of the American Society of Clinical Oncology, May 15-18, 1995, Los Angeles, CA.
This article has been cited by other articles:
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. (1999). Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors. Pharmacological Reviews 51: 691-744 [Abstract] [Full Text]
FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT
¸ 1999 American Society of Clinical Oncology. "
Larry Meneely |
